Gut microbiota and metabolites of cirrhotic portal hypertension: a novel target on the therapeutic regulation.

Future explorations should further characterize the alteration of the fecal microbiome and metabolite profiles in PH and elucidate the regulatory mechanism of the intestinal microbiome, gut-derived metabolites and gut microbiota targeted pharmaceutical treatments involved in PH.